Cajal Neuroscience

Executive Summary

Cajal Neuroscience is an early-stage drug discovery company leveraging human genetics and functional genomics to tackle neurodegenerative diseases. By building high-resolution molecular maps of aging and diseased brains, the company identifies and prioritizes novel druggable targets. Its integrated platform combines human data with advanced experimental models to de-risk therapeutic pathways, addressing the complexity of conditions like Alzheimer's and Parkinson's. With $96 million raised, Cajal is advancing preclinical programs toward IND-enabling studies. The company's approach has the potential to unlock new target classes and improve clinical success rates, though it remains in early development with no clinical candidates yet.

Upcoming Catalysts (preview)

• Q1 2027Lead Program IND Filing50% success
• Q2 2026New Preclinical Data at Major Conference (e.g., AD/PD)80% success
• Q3 2026Partnership or Collaboration Announcement40% success